All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit the MPN Advocates Network.
During the Society of Hematologic Oncology (SOHO) 2021 Annual Meeting, the MPN Hub spoke with Olatoyosi Sobulo Odenike, The University of Chicago, Chicago, US. We asked, What are the key considerations in the management of MPN in accelerated phase (MPN-AP)?
What are the key considerations in the management of MPN-AP?
Odenike discusses MPN-AP, she mentions allogeneic stem cell transplants and challenges such as short survival rates in patients.
Results from a phase II trial of decitabine and ruxolitinib for patients with MPN-AP/BP
Myeloproliferative neoplasms (MPN) are chronic malignancies that can transform to the accelerated phase (AP) with 10–19% blast cells or the blast phase (BP), with...
Venetoclax combinations for patients with accelerated and blast phase MPNs
Myeloproliferative neoplasms (MPN) can develop into an accelerated phase (AP) or blast phase (BP).
Subscribe to get the best content related to MPN delivered to your inbox